吉西他滨联合顺铂治疗晚期三阴性乳腺癌患者的效果观察  

Effect of gemcitabine combined with cisplatin on advanced triple negative breast cancer

作　　者：孔庆彧 KONG Qing-yu(Department Two of Internal Medicine,Fushun Tumor Hospital,Fushun 113000,China)

机构地区：[1]抚顺市肿瘤医院内二科,113000

出　　处：《中国现代药物应用》2020年第22期109-111,共3页Chinese Journal of Modern Drug Application

摘　　要：目的探讨吉西他滨联合顺铂治疗晚期三阴性乳腺癌(TNBC)患者的效果。方法64例晚期乳腺癌患者,根据病情分为TNBC组(TNBC患者)与nTNBC组(非TNBC患者),各32例。两组患者均采用吉西他滨联合顺铂治疗。比较两组患者的临床疗效,治疗前后血清血管内皮生长因子(VEGF)、血管内皮生长因子受体1(VEGFR1)、基质金属蛋白酶-9(MMP-9)、基质金属蛋白酶组织抑制剂-1(TIMP-1)水平,不良反应发生情况与随访结局。结果TNBC组的总有效率53.13%明显高于nTNBC组的28.13%,差异具有统计学意义(χ^2=4.176,P<0.05)。两组临床获益率比较,差异无统计学意义(P>0.05)。治疗后,两组血清VEGF、VEGFR1、MMP-9、TIMP-1水平均较治疗前下降,但TNBC组TIMP-1(50.02±17.33)ng/ml高于nTNBC组的(40.25±19.17)ng/ml,差异具有统计学意义(P<0.05);两组VEGF、VEGFR1、MMP-9水平比较,差异无统计学意义(P>0.05)。两组胃肠道反应、血常规异常、肝功能损害、神经毒性的发生率比较,差异无统计学意义(P>0.05)。TNBC组随访2~23个月,中位随访时间为11.40个月,4例(12.50%)死亡,中位无进展生存期(PFS)为5.49个月。nTNBC组随访3~25个月,中位随访时间为12.19个月,3例(9.38%)死亡,中位PFS为6.03个月。结论吉西他滨联合顺铂治疗晚期TNBC具有较好效果,有效率甚至可高于nTNBC。Objective To discuss the effect of gemcitabine combined with cisplatin on patients with advanced triple negative breast cancer(TNBC).Methods A total of 64 patients with advanced triple negative breast cancer were divided into TNBC group(TNBC patients)and nTNBC group(non-TNBC patients)by their condition of disease,with 32 cases in each group.Both groups were treated with gemcitabine combined with cisplatin.The clinical efficacy,vascular endothelial growth factor(VEGF),vascular endothelial growth factor receptor 1(VEGFR1),matrix metalloproteinase-9(MMP-9)and tissue inhibitor of metalloproteinase-1(TIMP-1)before and after treatment,occurrence of adverse reactions and follow-up outcome were compared between the two groups.Results The total effective rate 53.13%of TNBC group was obviously higher than 28.13%of nTNBC group,and the difference was statistically significant(χ^2=4.176,P<0.05).There was no statistically significant difference in clinical benefit rate between the two groups(P>0.05).After treatment,VEGF,VEGFR1,MMP-9 and TIMP-1 of the two groups were lower than those before treatment,but TIMP-1(50.02±17.33)ng/ml of TNBC group was higher than(40.25±19.17)ng/ml of nTNBC group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in VEGF,VEGFR1 and MMP-9 between the two groups(P>0.05).There was no statistically significant difference in incidence of gastrointestinal reaction,abnormal blood routine,liver function damage and neurotoxicity between the two groups(P>0.05).TNBC group was followed up for 2-23 months,the median follow-up time was 11.40 months,4 cases(12.50%)died,and the median progressionfree survival(PFS)was 5.49 months.nTNBC was followed up for 3-25 months,the median follow-up time was 12.19 months,3 cases(9.38%)died,and the median PFS was 6.03 months.Conclusion Gemcitabine combined with cisplatin has a better effect in the treatment of advanced TNBC,and the effective rate may even be higher than that of nTNBC.

关 键 词：吉西他滨 顺铂 三阴性晚期乳腺癌 

分 类 号：R737.9[医药卫生—肿瘤]